Catalent has approved AveXis that, a Novartis\nCompany to use its brand-new commercial manufacturing center near\nBaltimore-Washington International Airport as an extra site production site for\nits spinal muscular atrophy (SMA) gene therapy Zolgensma\u00ae (onasemnogene\nabeparvovec-xioi).<\/p>\n\n\n\n
A collaboration contract was signed by Catalent\nand AveXis to ensure long term strategic agreement but has not been disclosed\nyet. AveXis will use the dedicated production space within Paragon\u2019s Harmans,\nMD, facility, a 151,000-square-foot old warehouse that Paragon changed into a\ncontract developing and a manufacturing site which opened in April.<\/p>\n\n\n\n
Andy Stober, senior VP of technical operations\nfor AveXis, stated that \u201cWe are pleased to add additional manufacturing\ncapacity and technical expertise through this collaboration as we rapidly scale\nup product production,\u201d and \u201cWe look forward to working with Catalent in\ncontinued service of the SMA community.\u201d<\/em><\/p>\n\n\n\n Pete Buzy, Catalent\u2019s president, gene therapy\nadded: \u201cThis collaboration allows us to leverage our new state-of-art GMP\ncommercial manufacturing facility and AAV development and scale-up expertise to\nsupport AveXis from the early development stage to this critical launch.”<\/em>\n<\/p>\n\n\n\n Catalent added that Paragon therapy will also\nserve method development for clinical supply of extra viral treatments in\nAveXis pipeline.\n\nThis\ncollaboration of AveXis with Paragon shows Avexis’s interest in the field in\nlooking far beyond the existing capacity to meet Zolgensma-related production\nrequirements. According to a data by Boulder County Assessor\u2019s Office AveXis\nhas been reported to pay $30 million for the site of Longmont in a sale on\nApril 2.\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":" Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma\u00ae (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been […]<\/p>\n","protected":false},"author":2,"featured_media":346,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,5,2,1],"tags":[127,126],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/345"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=345"}],"version-history":[{"count":2,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/345\/revisions"}],"predecessor-version":[{"id":348,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/345\/revisions\/348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/346"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}